Veraxa Biotech AG · NASDAQ:VRXA
Veraxa Biotech — SPAC Merger (April 2025)
28 slides from Veraxa Biotech's SPAC merger presentation, Apr 23, 2025
Slide 1: Unlocking Next-Generation Therapies to Treat Cancer
U n l o c k i n g N e x t - G e n e r a t i o n Th e r ap i e s t o T r e a t C an c e r I n v e s t o r P r e s e n t a t i o n
Slide 2: Today's Speakers: Voyager Acquisition Corp.
T o d a y ’ s S p e a k e r s : V o y a g e r Acq u i s i t i o n C o r p. ( N A S D A Q : V A C H) W a rr e n H o sse i n i o n C h a i r m a n A d ee l R ou f P r es i d e n t , CE O a n d D i r e c t o r C ha i r m a n o f C a r d i o D i ag n o s t i cs , I n c . ( N AS D A Q : C D I O) D i r e
Slide 3: Today's Speakers: VERAXA
T o d a y ’ s S p e a k e r s : V E R A X A D r . C h r i s t o p h A n t z C E O a n d C o - F o un d e r O l i ve r R . B a um a n n C h a i r m a n C E O an d C o - F o un d e r o f V E R AX A B i o t e c h F o r m e r M a n ag i n g D i r e c t o r o f A c ou s ia T h e r a pe u t i c s F o r m
Slide 4: Disclaimer and Forward-Looking Statements
D i s c l a i m e r a nd F o r w a r d - L oo k i ng S t a t e m e n ts 4 Fo r w a r d - L oo ki ng S t a te m e n t s T h is p r e s e n t a t i o n c o n t a i n s c e r t a in f o r wa r d - l o o k i n g s t a t e m e n t s w i t h in t h e m e a n i n g o f t h e f e d e r a l s e c u r i t i e
Slide 5: Transaction Summary
T r a n sa ct i o n S u m m a r y E s t i m a t e d S o u r c e s & U s e s B u s i n e s s C o m b i na t i o n S t r uc t u r e • V o y ager A c qu is i t i o n C o r p i n t end s t o c omp l e t e a bu s i ne s s c omb i na t i o n w i t h V E R A XA , a l ead i n g c ompan y i n t h e ne x t on
Slide 6: Unlocking Next-Generation Therapies to Treat Cancer
U n l o c k i n g N e x t - G e n e r a t i o n Th e r ap i e s t o T r e a t C an c e r I n v e s t o r P r e s e n t a t i o n
Slide 7: Vision and Mission
V i s ion A w o r l d w h e r e c a n c e r i s n o l ong e r a l i f e - t h r e a te n i n g d i a gno si s but a ma n a g e a b l e c o nd it i o n — w h e r e p a ti e n t s l i v e w i t h out f e a r , e m po w e r e d b y g r oun d b r e a k i n g t h e r a p i es . M i s s ion A t V E R A X
Slide 8: VERAXA is Leading the Next Oncology Revolution
V E R A X A i s L e a d i ng t he N e x t O nc o l o g y R e v o l ut i o n $4 3 1 B G l o b a l S o l i d T u m o r M a r k e t i n 2 0 2 5 3 E x p e c t e d C li n i c a l - S t a g e D r u g P r o g r a ms i n 2 0 2 9 19 . 7 % G l o b a l M a r k e t C A G R 2 0 2 5 - 2 0 3 3 22 P a t e n t f a m
Slide 9: VERAXA's Solution to Cancer Therapy
V E R A X A ’ s S o l ut i o n t o C a n c e r T h e r a p i e s Ad v a nc e d C a nc e r T h e r a p e u t i cs T o x i c i t y C h e m o t h e r a py E f f i c a cy B i T AC ( V E R A X A) E f f i c a cy T o x i c i t y ▪ V E R A X A ’ s B r e a k t h r o u g h B i T AC ( B i - T a r g ete d An ti
Slide 10: TAM of $431B for VERAXA's Solution
0 200 400 600 800 1000 1200 1600 1400 1800 2000 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 T AM o f $ 43 1 B f o r V E R A X A’ s S o l u t i o n G l o b a l S o li d T u m o r M a r k e t $ 1 6 bn $ 5 7 bn $ 1 8 bn $ 11 2 bn $3 4 b n $1 6 9 b n 2 0 2 5 C AGR 2 0 3 0 S o u r c e : M o r
Slide 11: Executive Leadership and Management Team
E x e cu t i v e L e a d e r s h i p a nd M a n a g e m e nt T e a m P r o f . R a l f B a r g o u C h a ir f o r T r a n s l a t i on a l O n c o l o g y U n i v e r s i t y C li n ic W u e r z bu r g P r o f . D im i t r i s T z a c h a n i s H e m a t o l o g i s t / M e d i c a l O n c o l o g i
Slide 12: Scientific Leadership
M a r i a n W ei s s , P h D D i r e c t or M i c r o f l u i d i c s 7 y e a r s in m i c r o f l u i d ic d e v l p m t . P h y s i c s M a x - P l a n k , U n i v . H e i d e l b e r g H a h n - S c h i c k a r d , V e l a b s T h e r a p e u t i c s S t effe n D i c k o p f , P h D D i r e c t o
Slide 13: First In Class Technology with One Vision
F i r s t I n C l a s s T e chn o l o g i e s w i t h O n e V i s i o n O u r A n t i b o d y D r u g C o n j u g a t e ( A D C ) t e c h n o l o g y s e l e c t i v e l y t a r g e t s a n d d e s t r o ys c a n c e r c e l l s w h i l e s p a r i n g h e a l t h y o n e s w i t h n o r e p o r t e
Slide 14: Severe Toxicity is the Problem in Cancer Therapy
S e v e r e T o x i c i ty i s t he P r o b l e m i n C a n c e r T h e r a p i e s S a m e Ma r k e r P R O B L E M S i n g l e C a n c er M a r k e r s a r e f o u n d o n He a l t h y C e l l s . A D C ( A n t i b o d y D r u g C o n j u g a t e) S a m e Ma r k e r S i ng l e M o l e cu l e T a r
Slide 15: VERAXA's Solution Eliminates the Problem
VER A X A ’ s S o l u t i on E l i m i n a te s t h e P r ob l e m D i f f e r e nt Ma r k e r S e l e c t i v e ma r k e r p a i r D i f f e r e nt Ma r k e r B i T A C T C E ( T - C e l l E n g a g e r ) B i T A C A D C ( A n t i bo d y D r u g C on j u g a t e ) S O L U T I O N A h i g h l y s p
Slide 16: VERAXA Demonstrates Preclinical Efficacy in Animal Models
VER A X A D e m o n s t r a t e s P r e c l i n i c a l E ff i c a c y i n A n i m a l Mo d e l s A d a p t e d f r o m G e is e t a l. 202 1 ( N a t u r e C o mm un i c a t i on s ): N O D S C I D m i c e i n j e c t e d w i t h l u c if e r a s e - p o s i t i v e M M . 1 S c e lls - T u m o r b e
Slide 17: VERAXA Technology Supercharged by Data-Rich AI
V E R A X A T e c h n o l o g i e s S u p e r c h ar g e d b y D a t a - R i c h AI T a r g e t B i o l o g y D r u gg a b i li ty T u m o r B i o l o g y D e v e l o p a b il i ty D r u g D e s i g n E f f i c a c y S a f e t y B i om a r k e r s C o m p e t i t i v e I n t e l li g e n c e C l i n
Slide 18: A Modular Platform for Cost-Effective Drug Development
A M o d u l a r P l a t f o r m f o r C os t - E ff e ct i v e D r u g D e v e l o pm e nt T o t a l nu m b er o f t a r g ets C e l l r e c e p t o r s i n c an c e r i n d i c a t i ons ~ 85 0 ~ 80 ~ 1 0 S o l i d t u m or ass o c i a t e d a n t i g e ns N u m b e r of t a r g e t s u s e d f or
Slide 19: IP Excellence Underpinning VERAXA's Technology
I P E x c e l l e nce U n d e r p i n n i n g V E R A X A ’ s T e c h n o l o g i e s T r a d e S e c r e t s 19 F r ee d om - t o - O p e r a t e A pp r o v e d p a t e n t s a n d p a t e n t a pp li c a t i o n s c o v e r i n g: − B i T A C - T C E s − B i T A C - A D C s − M i c r o f l u i d i
Slide 20: Surpassing the Limits of Conventional Cancer Therapy
S u r p a ss i n g the L i m i ts of C o n v e n t i o na l C a nc e r T h e r a p i e s E f f i c a cy Tu m or S p e ci f i c i t y ( S a f e t y ) B i T A C - T C E Bi T A C - A D C R e q u i r e t u m o r - s p e c i f i c p r o t e a s e ▪ A l l m aj o r A D C d e v e l o p e r s u s e t e c h n
Slide 21: Converting VERAXA's Technology into Commercial Value
C o n v e r t i ng V E R A X A ’ s T e c h n o l o g i e s i n t o C o mm e r c i a l V a l u e A D C T C E T - C e ll E n g a g e r A n t i b o d y D r u g C o n j u g a t e s B i T A C 202 5 202 6 202 7 202 8 202 9 203 0 P o t e n t i a l C o m p a n y V a l u e ( Q u a l it a t i v e ) P a r t n
Slide 22: Redefining and Rapidly Expanding Pipeline
R e d e f i n i ng a nd R a p i d l y E x p a n d i ng P i p e l i n e * A n t i c i p a t e d p a r t n e r s h i p s du e t o i n t e r e s t e d p a r t i e s 22 2 0 3 0 2 0 2 9 2 0 2 8 2 0 2 7 2 0 2 6 2 0 2 5 D i se a s e T y p e P a r t n e r P r o g r a m P h2 P h1 P h1 P r e c l i n i c a l P
Slide 23: VERAXA: Positioned for Transformative Growth
V E R A X A : P o s i t i on e d f o r T r a n s f o r ma t i v e G r o w t h V E R AXA i s po i s e d t o a ch i e v e f u t u r e r e v e n u e g r o w t h t h r o u gh a c o m b i n a t i o n o f po te n t i a l p a r t n e r s h i p s a n d c o n t i n u e d d e v e l o p m e n t of i t s p r op
Slide 24: Comparable M&A Transactions
C o m p a r a b l e M & A T r a n sa c t i o ns * M a j o r i t y o f D e a l s a r e E x e c u t e d P r e - C l i n i ca l S t a g e s A D C - D e a l s A n t i bo d y D r u g C o n j u g a t es 24 T C E D e a l s B i - s p e c i f i c A n t i b o d i es C on t e n t S t a g e Y ea r I ss u e r A
Slide 25: Next-Generation Therapeutics Investment Highlights
N e x t - G e n e r a t i o n T h e r a p i e s T a r g e t i n g f i v e o f t h e m o s t p r e v a l e n t a n d a g gr e ssi v e s o l i d t u m o r i n d i c a t i o n s . S c a l a b l e M u l t i - P l a t f o r m T e c hn o l o g y B r o ad a p p l i c a t i o n a c r o s s m a j o r m a l i
Slide 26: References
1. G l ob a l S o li d T u m o r M a r k e t F o r e c a s t Ma r k e t D a t a F o r e c a s t , 2 0 2 4 : ( h tt p s : // w w w . ma r k e t d a t a f o r e c a st . c o m / ma r k e t - r e p o r ts / s o l i d - t u m o r - m a r k e t ) 2. A n t i bod y D r u g C on j u g a t e s M a r k e t O
Slide 27: Comparable M&A Transactions Sources
9 . C o m p a r a b l e M & A T r a n s a c t i on s : h tt p s : // w w w . o x f o r db i o t h e r a p e u ti c s . co m / n e w s - e v e n ts / o x f o r d - b i o t h e r a p e u ti cs - e n te r s - i n t o - a - st r a t e g i c - co l l a bo r a ti o n - w i t h - r och e - t o - d i s c o
Slide 28: h tt p s : // w w w . st on c o
h tt p s : // w w w . 1 st on c o l og y . c o m / b l o g / s o t i o - e x pand s - a d c - p i p e l i n es y n a ff i x - co ll a bo r a ti on - t o - d e v e l o p - t w o - no v e l - b i s p e c i f i c - c a n d i d a t e s - s o t 1 1 2 s o t 1 1 3 1 2 3 4 6 5 1 1 4 2 / ? t = i n t h tt p s